Midway Pharmaceuticals, founded with a mission to innovate non-antibiotic therapies for gastrointestinal diseases, focuses on developing treatments for conditions such as Crohn's disease, ulcerative colitis, necrotizing enterocolitis, and other inflammatory bowel diseases. The company is also pioneering in the area of bone health through its product MidwayBiome, a daily dietary supplement designed to enhance bone health in post-menopausal women by leveraging the interactions between the gut and gut bacterial populations.
Notable figures affiliated with Midway Pharmaceuticals include leading researchers and experts in gastroenterology and microbiome science. The company has garnered significant attention and investment from key players in the pharmaceutical industry, reflecting confidence in its innovative approach. Midway Pharmaceuticals has made impactful strides in understanding the gut microbiome's role in overall health, positioning itself as a leader in non-antibiotic gastrointestinal therapies and contributing to advancements in both gastrointestinal and bone health.
